Salesforce.com to B...
Health Care: Drugs
Akorn Inc. (AKRX: NASDAQ)
$13.75 0.45 | 3.38%
06/04/12 - 02:55 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:31.74
Price Earnings Comparisons:
| AKRX | Sector Avg. | S&P 500 |
|---|---|---|
| 31.74 | 31.70 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 8.94 | 95.30 | 1163.89 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 58.50 | 0.46 | 0.13 |
| Net Income | 97.10 | -6.42 | 0.00 |
| EPS | 86.40 | -6.00 | 0.00 |
Earnings for AKRX:
| EBITDA | 40.46M |
| REVENUE | 136.92M |
Average Earnings Estimates
| Qtr (06/12) | Qtr (09/12) | FY (12/12) | FY (12/13) | |
|---|---|---|---|---|
| Average Estimate | $0.10 | $0.11 | $0.49 | $0.62 |
| Number of Analysts | 1 | 1 | 2 | 2 |
| High Estimate | $0.10 | $0.11 | $0.55 | $0.67 |
| Low Estimate | $0.10 | $0.11 | $0.42 | $0.56 |
| Prior Year | $0.04 | $0.08 | $0.28 | $0.49 |
| Growth Rate (Year over Year) | 150.00% | 37.50% | 73.21% | 26.80% |
Portfolios with AKRX
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 16
- UserGFNN Stockdiagnostics 11
- Userpharmacy
- UserGFNN Stockdiagnostics 4
- UserDIGGITY PORTFOLIO
- UserGFNN Stockdiagnostics
- ContributorStocks At New 52-Week Highs...
- UserDivatrades
- Contributor5 Stocks Under-$10 Setting ...
- UserMister 600
Latest AKRX Headlines from TheStreet
- Akorn Stock Hits New 52-Week High (AKRX) 05.30.12 | 02:05 pm
- 3 Stocks Hit 52-Week Highs 05.15.12 | 02:05 pm
- Akorn Stock Hits New 52-Week High (AKRX) 05.15.12 | 09:05 am
- Akorn Reaches New 52-Week High (AKRX) 02.29.12 | 10:02 am
- Akorn Rises On Unusually High Volume (AKRX) 02.13.12 | 04:02 pm
- 3 Stocks Hitting 52-Week Highs: Akorn, Sunoco Logistics, Cincinnati Financial 02.10.12 | 02:02 pm
- Akorn Reaches New 52-Week High (AKRX) 02.10.12 | 12:02 pm
- Akorn Reaches New 52-Week High (AKRX) 02.01.12 | 09:02 am
- Akorn Reaches New 52-Week High (AKRX) 12.19.11 | 10:12 am
- 6 Stocks at New 52-Week Highs 12.13.11 | 01:12 pm
Press Releases for AKRX
- Akorn Reports Record First Quarter 2012 Financial Results - Business Wire 05.08.12 | 06:05 am
- Akorn Announces The Approval And Launch Of Generic Vancocin® - Business Wire 04.10.12 | 06:04 am
- Brinson Patrick Securities Initiates Research Coverage Of Akorn, Inc. - PR Newswire 03.22.12 | 03:03 pm
- Akorn Reports 2011 Fourth Quarter And Year-End Financial Results - Business Wire 03.06.12 | 07:03 am
- Akorn Announces The Appointment Of Dr. Adrienne Graves, Ph.D. To Its Board Of Directors - Business Wire 03.05.12 | 08:03 pm
- Akorn Completes The Acquisition Of Certain Assets Of Kilitch Drugs In India - Business Wire 02.28.12 | 07:02 pm
- Akorn Provides Financial Guidance For 2012 - Business Wire 01.17.12 | 07:01 am
- Akorn Acquires Three Hospital-Based Branded Injectables From Lundbeck - Business Wire 12.22.11 | 01:12 pm
- Akorn Reports Record Third Quarter 2011 Financial Results - Business Wire 11.01.11 | 07:11 am
- Akorn Enters Into An Agreement To Acquire Certain Assets Of Kilitch Drugs In India - Business Wire 10.06.11 | 12:10 am
Partner Headlines for AKRX
- Zacks Releases Four Powerful ''Buy'' Stocks: BE Aerospace, Yum! Brands, Akorn and H.B. Fuller - Press Releases - Zacks 02.08.12 | 09:02 am
- Akorn, Inc. - Momentum - Zacks 02.08.12 | 01:02 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 01.20.12 | 09:01 am
- End-of-Day Market Summary for December 23, 2011 - Benzinga 12.23.11 | 04:12 pm
- Hearing Akorn Recent Weakness Attributed to FDA Inspection Letter - Benzinga 12.23.11 | 11:12 am
- Akorn Acquires Three Hospital-Based Branded Injectables from Lundbeck; Expected To Add Approximately $30-$35M in 2012 - Benzinga 12.22.11 | 01:12 pm
- Piper Jaffray Maintains Overweight, $12 Target on Akorn - Benzinga 12.15.11 | 09:12 am
- Akorn, Inc - Aggressive Growth - Zacks 11.11.11 | 01:11 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.03.11 | 09:11 am
- These NASDAQ Rockets Should Be In Your Portfolio - Seeking Alpha 10.19.11 | 09:10 am
